ANN ARBOR, MI / ACCESSWIRE / March 26, 2020 / ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ:NDRA), the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS™), today provided a business update and reported fourth quarter and full year 2019 financial results.

"I am proud of the many, notable achievements ENDRA has made over the last year, which have given us strong forward momentum as we move towards our goal of bringing our breakthrough liver fat measurement application of the TAEUS technology to the EU and U.S. markets," said Francois Michelon, Chairman and Chief Executive Officer. "Like others in our industry, we continue to monitor and evaluate the near and long term potential impacts of the COVID19 pandemic, and are making required adjustments to ensure ENDRA remains well positioned to deliver on our plans."

Key 2019 Highlights

Submitted CE Mark technical file for TAEUS liver device in the EU.

Completed two-part, first in-human feasibility study of TAEUS liver application at Robarts Research Institute and reported top-line results.

Announced new clinical study partnerships with two leading clinical institutions.

Expanded leadership team with new Chief Commercial Officer, Renaud Maloberti, and Vice President of Engineering and Programs, Amy Sitzler.

Increased intellectual property portfolio to 64 filed, issued and licensed patents and pending patent applications.

Subsequent Events in Q1 2020

Received CE Mark Approval for TAEUS FLIP (Fatty Liver Imaging Probe) System targeting Non-Alcoholic Fatty Liver Disease ("NAFLD") and Non-Alcoholic Steatohepatitis ("NASH").

Renewed collaboration agreement with the GE Healthcare unit of General Electric Company ("GE"), extending the agreement's term to January 2021.

Expanded Scientific Advisory Board with the addition of Raza Malik, M.D., Director of Hepatology and Associate Chief of the Division of Gastroenterology at Tufts Medical Center in Boston.

"Results generated from our feasibility study in 2019 and strong clinical reception to our ongoing pre-commercial activities have reinforced our excitement about the potential for the TAEUS liver fat application. We continue to believe it is well positioned to address a significant clinical need and technology gap for a safe, non-invasive, cost-effective and point-of-care tool to assess liver fat in patients with chronic liver conditions like NAFLD and NASH," continued Michelon. "With the receipt of the CE Mark approval for TAEUS liver system, which was earlier than anticipated, we are looking forward to ramping up our initial commercialization efforts in Europe and making our regulatory filing in the U.S. in the second quarter of 2020."

Financial Results for Year Ended December 31, 2019

Operating expenses increased to $10.8 million in FY 2019 from $9.0 million in FY 2018. The increase was due almost exclusively to increased costs associated with the development of our TAEUS product line.

Net loss in FY 2019 totaled $13.3 million, and after a non-cash deemed dividend related to the issuance of preferred stock of $4.2 million the loss was $17.5 million, or ($2.34) per basic and diluted share, as compared to a net loss of $9.8 million, or ($2.17) per basic and diluted share in FY 2018.

Cash at December 31, 2019 totaled $6.2 million, as compared to $6.5 million at December 31, 2018, with no long-term debt outstanding. The decrease of cash is a result of our spending for normal operations offset by our funding throughout the year.

2020 Goals & Milestones

Initiate EU commercial strategy with an emphasis on establishing clinical evaluation reference sites in target markets and executing TAEUS product marketing communication and education campaigns.

Bolster and finalize 510(k) regulatory package with important additional verification testing targeting submission to the Food and Drug Administration (FDA) in the second quarter of 2020.

Begin measured investment in commercial activities and organization to support pre-launch and early commercial stage activities in partnership with GE.

Engage additional clinical partners and grow the clinical evidence base supporting TAEUS utility in a clinical setting.

Current cash position expected to be sufficient to fund operations through initial commercialization activities.

Conference Call and Webcast Access
Management will host a conference call and webcast today at 4:30 p.m. ET to discuss the results and provide an update on recent corporate developments.

Dial-in Number
U.S./Canada Dial-in Number: 844-602-0380
International Dial-in Number: 862-298-0970

Replay Dial-in Number: 877-481-4010
Replay International Dial-in Number: 919-882-2331
Replay Passcode: 33509

A telephone replay will be available March 26, 2020 through 4:30 p.m. ET on April 9, 2020.

A live audio webcast will be available through the Events and Presentations page of the Investors section of the company's website atwww.endrainc.com. A replay of the webcast will be available on the website for 90 days.

About ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc. is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS™), a ground-breaking technology that mirrors some applications similar to CT or MRI, but at 50X lower cost, at the point of patient care. TAEUS is designed to work in concert with one million ultrasound systems in global use today. TAEUS is initially focused on the measurement of fat in the liver, as a means to assess and monitor NAFLD and NASH, chronic liver conditions that affect over 1 billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.www.endrainc.com

Forward-Looking Statements
All statements in this release that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "goal," "estimate," "anticipate" or other comparable terms. Examples of forward-looking statements include, among others, estimates of the timing of future events and achievements, such as the expectations listed above under the heading "2020 Guidance"; making our 510(k) submission with the FDA and commercializing the TAEUS device; and expectations concerning ENDRA's business strategy. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including, among others, our ability to develop a commercially feasible technology; receipt of necessary regulatory approvals; the impact of COVID-19 on our business plans; our ability to find and maintain development partners, market acceptance of our technology, the amount and nature of competition in our industry; our ability to protect our intellectual property; and the other risks and uncertainties described in ENDRA's filings with the Securities and Exchange Commission. The forward-looking statements made in this release speak only as of the date of this release, and ENDRA assumes no obligation to update any such forward-looking statements to reflect actual results or changes in expectations, except as otherwise required by law.

Company Contact:

David Wells
Chief Financial Officer
(734) 997-0464
investors@endrainc.com
www.endrainc.com

Media & Investor Relations Contact:

MacDougall
Amanda Houlihan
(781) 235-3060
endra@macbiocom.com

ENDRA Life Sciences Inc.
Consolidated Balance Sheets

 
December 31,
 
 
December 31,
 

Assets

 
2019
 
 
2018
 

Assets

Cash

 
$
6,174,207
 
 
$
6,471,375
 

Prepaid expenses

 
 
116,749
 
 
 
145,424
 

Inventory

 
 
113,442
 
 
 
59,444
 

Other current assets

 
 
130,701
 
 
 
273,315
 

Total Current Assets

 
 
6,535,099
 
 
 
6,949,558
 

Other Assets

Fixed assets, net

 
 
236,251
 
 
 
273,233
 

Right of use assets

 
 
404,919
 
 
 
–
 

Total Assets

 
$
7,176,269
 
 
$
7,222,791
 

Liabilities and Stockholders' Equity

Current Liabilities:

Accounts payable and accrued liabilities

 
$
1,708,525
 
 
$
974,583
 

Convertible notes payable, net of discount

 
 
298,069
 
 
 
–
 

Lease liabilities, current portion

 
 
66,193
 
 
 
–
 

Total Current Liabilities

 
 
2,072,787
 
 
 
974,583
 

Long Term Debt:

Lease liabilities

 
 
342,812
 
 
 
–
 

Total Long Term Debt

 
 
342,812
 
 
 
–
 

Total Liabilities

 
 
2,415,599
 
 
 
974,583
 

Stockholders' Equity

Series A Convertible Preferred Stock, $0.0001 par value; 10,000 shares authorized; 6,338.490 shares issued and outstanding

 
 
1
 
 
 
–
 

Series B Convertible Preferred Stock, $0.0001 par value; 1,000 shares authorized; 351.711 shares issued and outstanding

 
 
–
 
 
 
–
 

Common stock, $0.0001 par value; 50,000,000 shares authorized; 8,421,401 and 7,422,642 shares issued and outstanding

 
 
842
 
 
 
742
 

Additional paid in capital

 
 
49,933,736
 
 
 
33,939,162
 

Stock payable

 
 
43,528
 
 
 
–
 

Accumulated deficit

 
 
( 45,217,437
)
 
 
(27,691,696
)

Total Stockholders' Equity

 
 
4,760,670
 
 
 
6,248,208
 

Total Liabilities and Stockholders' Equity

 
$
7,176,269
 
 
$
7,222,791
 

ENDRA Life Sciences Inc.
Consolidated Statements of Operation

 
Year Ended
 
 
Year Ended
 

 
December 31,
 
 
December 31,
 

 
2019
 
 
2018
 

Revenue

 
$
–
 
 
$
6,174
 

Cost of Goods Sold

 
 
–
 
 
 
–
 

Gross Profit

 
 
–
 
 
 
6,174
 

Operating Expenses

Research and development

 
 
6,574,999
 
 
 
4,722,465
 

Sales and marketing

 
 
412,434
 
 
 
262,641
 

General and administrative

 
 
3,856,159
 
 
 
3,752,535
 

Impairment of inventory

 
 
–
 
 
 
287,541
 

Total operating expenses

 
 
10,843,592
 
 
 
9,025,182
 

Operating loss

 
 
(10,843,592
)
 
 
(9,019,008
)

Other Expenses

Amortization of debt discount

 
 
(2,355,469
)
 
 
(729,241
)

Other expense

 
 
(106,903
)
 
 
(48,012
)

Total other expenses

 
 
(2,462,372
)
 
 
(777,253
)

Loss from operations before income taxes

 
 
(13,305,964
)
 
 
(9,796,261
)

Provision for income taxes

 
 
–
 
 
 
–
 

Deemed dividend related to Preferred Stock

 
$
( 4,219,777
)
 
 
–
 

Net Loss attributable to common stockholders

 
$
( 17,525,741
)
 
$
(9,796,261
)

Net loss per share – basic and diluted

 
$
(2.34
)
 
$
(2.17
)

Weighted average common shares – basic and diluted

 
 
7,499,984
 
 
 
4,504,873
 

ENDRA Life Sciences Inc.
Consolidated Statements of Cash Flows

 
Year Ended
 
 
Year Ended
 

 
December 31,
 
 
December 31,
 

 
2019
 
 
2018
 

Cash Flows from Operating Activities

Net loss

 
$ 
(13,305,964
)
 
$ 
(9,796,261
)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization

 
 
80,577
 
 
 
68,316
 

Common stock, options and warrants issued for services

 
 
1,399,547
 
 
 
1,367,762
 

Amortization of debt discount

 
 
2,355,469
 
 
 
729,241
 

Impairment of other assets

 
 
249,256
 
 
 
–
 

Impairment of inventory

 
 
–
 
 
 
287,541
 

Amortization of right of use assets

 
 
34,434
 
 
 
–
 

Changes in operating assets and liabilities:

Increase in accounts receivable

 
 
–
 
 
 
6,850
 

Increase in prepaid expenses

 
 
28,675
 
 
 
(77,928
)

Decrease in lease liability

 
 
(30,348
)
 
 
–
 

Increase in inventory

 
 
(53,998
)
 
 
(155,305
)

Decrease in other asset

 
 
(106,642
)
 
 
(259,066
)

Increase in accounts payable and accrued liabilities

 
 
760,143
 
 
 
126,368
 

Net cash used in operating activities

 
 
(8,588,851
)
 
 
(7,702,481
)

Cash Flows from Investing Activities

Purchases of fixed assets

 
 
(43,595
)
 
 
(100,000
)

Net cash used in investing activities

 
 
(43,595
)
 
 
(100,000
)

Cash Flows from Financing Activities

Proceeds from senior secured convertible promissory notes, net of fees

 
 
2,490,501
 
 
 
935,300
 

Proceeds from issuance of Series A Convertible Preferred Stock

 
 
5,344,257
 
 
 
–
 

Proceeds from issuance of Series B Convertible Preferred Stock

 
 
375,520
 
 
 
–
 

Proceeds from issuance of common stock

 
 
125,000
 
 
 
7,736,678
 

Net cash provided by financing activities

 
 
8,335,278
 
 
 
8,671,978
 

Net decrease in cash

 
 
(297,168
)
 
 
869,497
 

Cash, beginning of period

 
 
6,471,375
 
 
 
5,601,878
 

Cash, end of period

 
$ 
6,174,207
 
 
$ 
6,471,375
 

Supplemental disclosures of cash items

Interest paid

 
$ 
–
 
 
$ 
40,085
 

Income tax paid

 
$ 
–
 
 
$ 
–
 

Supplemental disclosures of non-cash items

Discount on convertible notes

 
$ 
2,490,501
 
 
$ 
587,541
 

Conversion of convertible notes and accrued interest

 
$ 
140,406
 
 
$ 
1,077,000
 

Exchange of balance in convertible notes and accrued interest for Series A preferred stock
 
$
1,943,195
 
 
 
 
 

Deemed Dividend
 
$
4,219,777
 
 
 
 
 

Right of use asset

 
$ 
404,919
 
 
$ 
–
 

Lease liability

 
$ 
409,005
 
 
$ 
–
 

SOURCE: ENDRA Life Sciences Inc.

ReleaseID: 582690

AUSTIN, TX / ACCESSWIRE / March 26, 2020 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced financial results for the fourth quarter and year ended December 31, 2019. The Company will hold a conference call today at 3:30 p.m. CT / 4:30 p.m. ET to discuss its results.

Highlights

Fourth quarter U.S. OverStitch™ Endoscopic Suturing System ("ESS") sales increased 33% to $4.4 million
Fourth quarter U.S. Endoscopy sales increased 31% to $5.6 million
Worldwide ESS sales for the full year 2019 increased 21% (23% in constant currency) to $28.3 million, representing 63% of our Endoscopy sales
Fourth quarter Orbera® Intragastric Balloon System ("IGB") sales increased 23% in the U.S. and 11% (13% in constant currency) worldwide

Todd Newton, CEO of Apollo, said, "The Endoscopic Suturing market developed rapidly in 2019 as evidenced by Apollo's 36% revenue growth for ESS products in the U.S. and 21% growth worldwide. Clinical publications providing evidence of the many applications for our ESS technology continued to expand during 2019, and Apollo's new single channel OverStitch device introduced in November 2018 is taking our technology to a broader group of physicians and locations. Our strategy in the near term is to withstand the unprecedented challenges presented by the COVID-19 pandemic, and then return our focus as swiftly as possible to increasing the user base of our technology and to improve our operating efficiency as we continue to scale the business."

Due to unprecedented global economic conditions and uncertainty resulting from the COVID-19 pandemic, the Company will not be providing an outlook for 2020 at this time. We are closely monitoring the global impact to the health systems where we conduct business and the slowdown in business activity related to COVID-19, and hope to provide better clarity about our outlook for 2020 on our first quarter results call. In response to the rapidly changing conditions resulting from the COVID-19 pandemic, we have taken steps to limit business activities, to limit spending and maintain only key business functions in order to continue to fulfill product orders and support our customers while also taking proactive measures to protect the health and safety of our employees and their families consistent with local guidelines.

U.S. ESS product sales increased 33% to $4.4 million in the fourth quarter of 2019 and 36% to $14.9 million in the full year of 2019. Outside the U.S. ("OUS") ESS product sales decreased 15% (13% in constant currency) to $3.0 million for the fourth quarter of 2019 due primarily to the timing of distributor orders, while increasing 8% (13% in constant currency) to $13.4 million in the full year of 2019. Worldwide, ESS product sales increased 8% (9% in constant currency) and 21% (23% in constant currency) for the fourth quarter and full year of 2019, respectively.

U.S. IGB sales increased 23% to $1.2 million for the fourth quarter of 2019 and decreased 4% to $5.2 million for the full year of 2019. OUS IGB product sales increased 7% (9% in constant currency) to $3.1 million and decreased 5% (2% in constant currency) to $11.7 million for the fourth quarter and full year of 2019, respectively. Our efforts to expand IGB therapy in the U.S. market and advance twelve-month therapy OUS improved in the fourth quarter leading to reported growth in both regions and lifting our full year results close to break even with the prior year. Worldwide, IGB sales increased 11% (13% in constant currency) and decreased 5% (3% in constant currency) for the fourth quarter and full year of 2019, respectively.

Worldwide Endoscopy product sales increased 9% (10% in constant currency) and 10% (12% in constant currency) for the fourth quarter and full year of 2019, respectively. ESS product sales represented 64% and 63% of total Endoscopy sales for the fourth quarter and full year of 2019, respectively. In the U.S., Endoscopy sales increased 31% to $5.6 million and 22% to $20.1 million for the fourth quarter and full year of 2019, respectively.

The divestiture of our Surgical products in December of 2018 reduced total revenues by $4.1 million and $13.7 million for the fourth quarter and full year of 2019, respectively. We divested the Surgical products line in order to strengthen Apollo's focus on our Endoscopy products, which we believe have high growth potential.

Gross margin for the fourth quarter of 2019 was 49%, compared to 47% for the fourth quarter of 2018. Gross margin for the full year of 2019 decreased to 51% compared to 55% for the full year of 2018 as a result of a greater proportion of our overall product sales coming from our ESS products, which realize a lower gross margin than our other products. Management has previously discussed its ongoing gross margin improvement initiative.

Total operating expenses decreased $11.2 million to $12.7 million for the fourth quarter of 2019 and decreased $24.1 million to $49.2 million for the full year of 2019 compared to the same periods of 2018. Excluding the one-time $7.8 million loss on divestiture of our Surgical products in December of 2018, the subsequent reduction in intangible asset amortization expense of $1.2 million and $5.0 million for the fourth quarter and full year of 2019, respectively resulting from this divestiture and a one-time $5.6 million settlement gain reported in the first quarter of 2019, total operating expenses decreased $2.3 million and $5.7 million for the fourth quarter and full year of 2019, respectively. This reduction in recurring operating expenses was the result of lower U.S. direct to consumer advertising and lower clinical trial costs as enrollment or other milestones were reached on the clinical studies that the Company is funding.

Net loss for the fourth quarter of 2019 was $7.2 million compared to $18.4 million for the fourth quarter 2018. For the full year, net loss was $27.4 million in 2019 compared to $45.8 million in 2018.

Cash, cash equivalents and restricted cash were $30.9 million as of December 31, 2019.

Conference Call

Apollo will host a conference call on March 26, 2020 at 3:30 p.m. Central Time / 4:30 p.m. Eastern Time to discuss Apollo's operating results for the fourth quarter and year ended December 31, 2019.

To participate in the conference call dial 844-369-8770 for domestic callers and +1-862-298-0840 for international callers. A live webcast of the conference call will be made available on the "Events and Presentations" section of our Investor Relations website: ir.apolloendo.com.

A replay of the webcast will remain available on Apollo's website, www.apolloendo.com, following the call.

Non-GAAP Financial Measures

To supplement our financial results, we are providing a non-GAAP financial measure, percentage revenue change in constant currency, which removes the impact of changes in foreign currency exchange rates that affect the comparability and trend of revenues compared to the same period of the prior year. Percentage revenue change in constant currency is calculated by translating current foreign currency sales at last year's exchange rate. This supplemental measure of our performance is not required by, and is not determined in accordance with GAAP.

We believe the non-GAAP financial measure included herein is helpful in understanding our current financial performance. We use this supplemental non-GAAP financial measure internally to understand, manage and evaluate our business, and make operating decisions. We believe that making non-GAAP financial information available to investors, in addition to GAAP financial information, may facilitate more consistent comparisons between the company's performance over time with the performance of other companies in the medical device industry, which may use similar financial measures to supplement their GAAP financial information. However, our non-GAAP financial measure is not meant to be considered in isolation or as a substitute for the comparable GAAP metric.

About Apollo Endosurgery, Inc.

Apollo Endosurgery, Inc. is a medical technology company focused on less invasive therapies to treat various gastrointestinal conditions, ranging from gastrointestinal complications to the treatment of obesity. Apollo's device-based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo's products are offered in over 75 countries today and include the OverStitch™ Endoscopic Suturing System, the OverStitch Sx™ Endoscopic Suturing System, and the ORBERA® Intragastric Balloon.

Apollo's common stock is traded on Nasdaq Global Market under the symbol "APEN". For more information regarding Apollo Endosurgery, go to: www.apolloendo.com.

Cautionary Note on Forward-Looking Statements

Certain statements in this press release are forward-looking statements that are subject to risks and uncertainties that could cause results to be materially different than expectations. In addition, there is uncertainty about the spread of the COVID-19 virus and the impact it may have on the Company's operations, the demand for the Company's products, global supply chains and economic activity in general. Important factors that could cause actual results to differ materially include: the advancement of Apollo products; development of enhancements to Apollo's existing products and technologies; market acceptance of Apollo's products; the execution of our gross margin improvement projects; the ability to collect future payments from ReShape; statements relating to the availability of cash for Apollo's future operations; and Apollo's ability to support the adoption of its products and broaden its product portfolio as well as other factors detailed in Apollo's periodic reports filed with the Securities and Exchange Commission, or SEC, including its Form 10-K for the year ended December 31, 2019. Copies of reports filed with the SEC are posted on Apollo's website and are available from Apollo without charge. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, Apollo disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.

Disclosure Information

Apollo uses the investor relations section of its website as a means of complying with its disclosure obligations under Regulation FD. Accordingly, we recommend that investors should monitor Apollo's investor relations website in addition to following Apollo's press releases, SEC filings, and public conference calls and webcasts.

APOLLO ENDOSURGERY, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Operations
(In thousands, except for share data)

 
Three Months Ended
December 31,
 
 
Year Ended
December 31,
 

 
2019
 
 
2018
 
 
2019
 
 
2018
 

 
(Unaudited)
 
 
(Unaudited)
 
 
 
 
 
 
 

Revenues (1)

 
$ 
11,989
 
 
$ 
15,182
 
 
$ 
50,713
 
 
$ 
60,854
 

Cost of sales

 
 
6,154
 
 
 
8,100
 
 
 
25,038
 
 
 
27,660
 

Gross margin

 
 
5,835
 
 
 
7,082
 
 
 
25,675
 
 
 
33,194
 

Operating expenses:

Sales and marketing

 
 
6,735
 
 
 
7,753
 
 
 
28,730
 
 
 
32,831
 

General and administrative

 
 
3,369
 
 
 
3,847
 
 
 
13,588
 
 
 
13,436
 

Research and development

 
 
2,139
 
 
 
2,895
 
 
 
10,384
 
 
 
12,176
 

Amortization of intangible assets

 
 
504
 
 
 
1,663
 
 
 
2,095
 
 
 
7,074
 

Settlement gain

 
 
–
 
 
 
–
 
 
 
(5,609
)
 
 
–
 

Loss on divestiture

 
 
–
 
 
 
7,770
 
 
 
–
 
 
 
7,770
 

Total operating expenses

 
 
12,747
 
 
 
23,928
 
 
 
49,188
 
 
 
73,287
 

Loss from operations

 
 
(6,912
)
 
 
(16,846
)
 
 
(23,513
)
 
 
(40,093
)

Other expenses:

Interest expense, net

 
 
1,203
 
 
 
1,083
 
 
 
4,052
 
 
 
4,063
 

Other (income) expense

 
 
(1,063
)
 
 
355
 
 
 
(408
)
 
 
1,440
 

Net loss before income taxes

 
 
(7,052
)
 
 
(18,284
)
 
 
(27,157
)
 
 
(45,596
)

Income tax expense

 
 
144
 
 
 
69
 
 
 
275
 
 
 
191
 

Net loss

 
$ 
(7,196
)
 
$ 
(18,353
)
 
$ 
(27,432
)
 
$ 
(45,787
)

Net loss per share, basic and diluted

 
$ 
(0.34
)
 
$ 
(0.84
)
 
$ 
(1.27
)
 
$ 
(2.31
)

Shares used in computing net loss per share, basic and diluted (2)

 
 
20,946,035
 
 
 
21,895,133
 
 
 
21,542,284
 
 
 
19,789,867
 

(1) Revenue between periods declined $4.1 million for the three months ended December 31, 2019 and $13.7 million for the year ended December 31, 2019 due to the divestiture of the Surgical product line in December 2018. See the product sales table for additional information by product group and geographic market.
(2) In June 2018, 4.3 million common shares were issued upon completion of a public offering. In August 2019, 1.0 million outstanding common shares were exchanged for a pre-funded warrant.

APOLLO ENDOSURGERY, INC. AND SUBSIDIARIES
Product Sales by Product Group and Geographic Market
Unaudited (In thousands)

 
Three Months Ended
December 31, 2019
 
 
Three Months Ended
December 31, 2018
 
 
% Increase / (Decrease)
 

 
U.S.
 
 
OUS
 
 
Total Revenues
 
 
U.S.
 
 
OUS
 
 
Total Revenues
 
 
U.S.
 
 
OUS
 
 
Total Revenues
 

ESS

 
$ 
4,446
 
 
$ 
3,026
 
 
$ 
7,472
 
 
$ 
3,353
 
 
$ 
3,571
 
 
$ 
6,924
 
 
 
32.6
%
 
 
(15.3
)%
 
 
7.9
%

IGB

 
 
1,157
 
 
 
3,126
 
 
 
4,283
 
 
 
939
 
 
 
2,914
 
 
 
3,853
 
 
 
23.2
%
 
 
7.3
%
 
 
11.2
%

Total Endoscopy

 
 
5,603
 
 
 
6,152
 
 
 
11,755
 
 
 
4,292
 
 
 
6,485
 
 
 
10,777
 
 
 
30.5
%
 
 
(5.1
)%
 
 
9.1
%

% Endoscopy

 
 
47.7
%
 
 
52.3
%
 
 
 
 
 
 
39.8
%
 
 
60.2
%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Surgical

 
 
–
 
 
 
42
 
 
 
42
 
 
 
2,436
 
 
 
1,703
 
 
 
4,139
 
 
 
(100.0
)%
 
 
(97.5
)%
 
 
(99.0
)%

Other

 
 
183
 
 
 
9
 
 
 
192
 
 
 
260
 
 
 
6
 
 
 
266
 
 
 
(29.6
)%
 
 
50.0
%
 
 
(27.8
)%

Total revenues

 
$ 
5,786
 
 
$ 
6,203
 
 
$ 
11,989
 
 
$ 
6,988
 
 
$ 
8,194
 
 
$ 
15,182
 
 
 
(17.2
)%
 
 
(24.3
)%
 
 
(21.0
)%

 
Year Ended
December 31, 2019
 
 
Year Ended
December 31, 2018
 
 
% Increase / (Decrease)
 

 
U.S.
 
 
OUS
 
 
Total Revenues
 
 
U.S.
 
 
OUS
 
 
Total Revenues
 
 
U.S.
 
 
OUS
 
 
Total Revenues
 

ESS

 
$ 
14,944
 
 
$ 
13,365
 
 
$ 
28,309
 
 
$ 
11,016
 
 
$ 
12,364
 
 
$ 
23,380
 
 
 
35.7
%
 
 
8.1
%
 
 
21.1
%

IGB

 
 
5,162
 
 
 
11,678
 
 
 
16,840
 
 
 
5,400
 
 
 
12,339
 
 
 
17,739
 
 
 
(4.4
)%
 
 
(5.4
)%
 
 
(5.1
)%

Total Endoscopy

 
 
20,106
 
 
 
25,043
 
 
 
45,149
 
 
 
16,416
 
 
 
24,703
 
 
 
41,119
 
 
 
22.5
%
 
 
1.4
%
 
 
9.8
%

% Endoscopy

 
 
44.5
%
 
 
55.5
%
 
 
 
 
 
 
39.9
%
 
 
60.1
%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Surgical

 
 
–
 
 
 
3,712
 
 
 
3,712
 
 
 
10,795
 
 
 
7,913
 
 
 
18,708
 
 
 
(100.0
)%
 
 
(53.1
)%
 
 
(80.2
)%

Other (1)

 
 
1,815
 
 
 
37
 
 
 
1,852
 
 
 
995
 
 
 
32
 
 
 
1,027
 
 
 
82.4
%
 
 
15.6
%
 
 
80.3
%

Total revenues

 
$ 
21,921
 
 
$ 
28,792
 
 
$ 
50,713
 
 
$ 
28,206
 
 
$ 
32,648
 
 
$ 
60,854
 
 
 
(22.3
)%
 
 
(11.8
)%
 
 
(16.7
)%

(1) Other U.S. revenue includes $1.3 million of transition and manufacturing services provided to ReShape for the year ended December 31, 2019.

Product sales percentage change in constant currency were as follows:

 
Three Months Ended
December 31, 2019
 
 
Year Ended
December 31, 2019
 

 
% Increase/Decrease
in Constant Currency
 
 
% Increase/Decrease
in Constant Currency
 

 
OUS
 
 
Total Revenues
 
 
OUS
 
 
Total Revenues
 

ESS

 
 
(13.1
)%
 
 
9.1
%
 
 
12.5
%
 
 
23.4
%

IGB

 
 
9.2
%
 
 
12.6
%
 
 
(1.6
)%
 
 
(2.5
)%

Total Endoscopy

 
 
(3.1)
%
 
 
10.3
%
 
 
5.5
%
 
 
12.3
%

Surgical

 
 
(97.5
)%
 
 
(99.0
)%
 
 
(50.2
)%
 
 
(79.0
)%

Other

 
 
33.8
%
 
 
(27.2
)%
 
 
23.9
%
 
 
80.6
%

Total revenues

 
 
(22.7
)%
 
 
(20.1
)%
 
 
(8.0
)%
 
 
(14.6
)%

Contacts:

Apollo Endosurgery, Inc.
Stefanie Cavanaugh, 512-279-5100
investor-relations@apolloendo.com

Darrow Associates Investor Relations
Matt Kreps, 214-597-8200
mkreps@darrowir.com

SOURCE: Apollo Endosurgery, Inc.

ReleaseID: 582692

WEST PALM BEACH, FL / ACCESSWIRE / March 26, 2020 / Solitron Devices, Inc. (OTC PINK:SODI) ("Solitron" or the "Company") today announced preliminary revenue and bookings for the fiscal 2020 fourth quarter and year ended February 29, 2020, expectations for fiscal year 2021, and the impact of the COVID-19 coronavirus on operations.

FISCAL 2020 FOURTH QUARTER HIGHLIGHTS

Net sales of $2.0 million in fiscal fourth quarter versus $2.9 million in prior year period
Net bookings of $2.1 million in fiscal fourth quarter versus $4.0 million in prior year period

FISCAL 2020 YEAR HIGHLIGHTS

Net sales of $9.2 million in fiscal 2020 versus $9.4 million in prior fiscal year
Net bookings of $11.2 million in fiscal 2020 versus $8.3 million in prior fiscal year
Cash and Securities increased to $1.5 million, or approximately $0.75 per share, at the end of fiscal 2020 from $0.5 million, or approximately $0.25 per share, at the end of fiscal 2019

CURRENT FISCAL YEAR 2021 EXPECTATIONS

Net sales of approximately $10.5 million in fiscal 2021
Net bookings of approximately $10 million in fiscal 2021
Expect a meaningful improvement in net income

For the fiscal 2020 fourth quarter, net sales were approximately $2.0 million versus $2.9 million in the fiscal 2019 fourth quarter. As noted in our January 22, 2020 press release, fiscal 2020 fourth quarter revenues were expected to be negatively impacted by supplier issues. For fiscal 2020 net sales were $9.2 million versus $9.4 million in fiscal 2019. During the fiscal 2020 fourth quarter we began to see improvement regarding supplier issues related to timely delivery and quality; however, in the first few weeks of the fiscal 2021 first quarter, we have begun to see an impact on our supply chain from the coronavirus.

Our wafer fab continued to make progress in its improvement plan during the fiscal 2020 fourth quarter. Additional issues that needed to be addressed arose during the quarter, which delayed completion. While there are still a few minor issues to complete, production levels were increased in the past few weeks. Completion of the plan allows the company to provide for its future requirements and to supply customers with specialized bipolar wafer lot needs.

Net bookings were $2.1 million in the fiscal 2020 fourth quarter, and $11.2 million in fiscal 2020, as compared to $4.0 million in the fiscal 2019 fourth quarter, and $8.3 million in fiscal 2019. The fiscal 2019 fourth quarter included an order under our largest program with Raytheon in excess of $3 million, while the fiscal 2020 fourth quarter did not. Historically we have received orders related to that defense program approximately every twelve months. In fiscal 2020 we received an order of approximately $3 million in June, just six months after the previous order, and we received an additional approximately $2 million order for parts in November.

We currently expect to receive the next order under the program of roughly $2.5 to $3.0 million during the fiscal 2021 first quarter. At this point, our current expectation for bookings in fiscal 2021 is approximately $10 million, which includes the expected fiscal first quarter order and assumes the next large order from Raytheon under the aforementioned program will be in fiscal 2022, although it may occur before the end of the fiscal year. As a reminder, timing is always uncertain with regard to the receipt of government/defense related contracts.

As a small manufacturing concern with high fixed costs, we believe we have excellent operating leverage if we can increase sales. Since new management took over, one of our primary focuses has been to expand our capabilities into newer products, including Silicon Carbide, and we are beginning to see the fruits of our efforts. In the last six months of fiscal 2020 we had bookings in excess of $1.2 million related to new initiatives.

Based on our current backlog, we expect to see a revenue increase in fiscal 2021 versus fiscal 2020, and a material improvement in net income. Our current estimate for fiscal 2021 revenues is approximately $10.5 million. If achieved, it would be the first time the Company has exceeded $10 million in fiscal year revenues since the company went through a reorganization more than 25 years ago. As a reminder, when current management took over, trailing twelve months sales were approximately $7.5 million.

As noted above our cash and securities as of the end of fiscal 2020 was approximately $1.5 million. Much of the increase in the fourth quarter was due to a decrease in accounts receivable. As of the fiscal 2020 yearend, we continue to have no debt and our accounts receivable exceeds our total current liabilities.

Update Related to COVID-19

In recent weeks, Solitron has taken a number of steps to address the impact of the COVID-19 coronavirus on our employees and their families, while still maintaining business operations. These steps include elimination of in-person meetings, social distancing, staggered breaks and lunches, cessation of all employee travel, daily temperature screening, visitor limitations, etc. Meanwhile, we have continued to monitor the situation nationally and in South Florida. Last week, Florida Governor Ron DeSantis ordered "non-essential" businesses in Palm Beach county, where Solitron is based, to shut down until further notice. Solitron is exempt from this order since we are classified as an essential business due to providing defense components to the US government and its prime contractors.

Last week President Trump signed into law the Families First Coronavirus Response Act (FFCRA), which takes effect April 1. Our current estimate is that up to 30% of our employees could be eligible to take paid sick time. While we expect most of the labor costs of those on sick time to be eligible for credits under the FFCRA, if all eligible employees avail themselves it would negatively impact production levels during the period. The FFCRA provides for two weeks of sick time for at risk employees and up to twelve weeks for those caring for children due to school closure. If the reduction lasts only two weeks, we do not expect any meaningful impact to our delivery schedules. Obviously, the situation remains fluid, so as circumstances change, we will respond accordingly.

We join with others in continuing to pray for the well being of our community, nation, and for all people worldwide who have been impacted by this virus, as well as those in leadership making decisions that impact everyone so dramatically.

These preliminary, unaudited revenue and bookings for the fiscal fourth quarter and fiscal year ended 2020 and 2019 are based on management's review of operations for those periods and the information available to the Company as of the date of this press release. An independent registered public accounting firm has not reviewed or performed any procedures with respect to the preliminary information presented for the fiscal quarters and fiscal years ended February 29, 2020, February 28, 2019, or February 28, 2018, nor completed the audit for the fiscal year ended February 28, 2017.

About Solitron Devices, Inc.

Solitron Devices, Inc., a Delaware corporation, designs, develops, manufactures and markets solid state semiconductor components and related devices primarily for the military and aerospace markets. The Company manufactures a large variety of bipolar and metal oxide semiconductor ("MOS") power transistors, power and control hybrids, junction and power MOS field effect transistors ("Power MOSFETS"), and other related products. Most of the Company's products are custom made pursuant to contracts with customers whose end products are sold to the United States government. Other products, such as Joint Army/Navy ("JAN") transistors, diodes and Standard Military Drawings voltage regulators, are sold as standard or catalog items. The Company was incorporated under the laws of the State of New York in March 1959 and reincorporated under the laws of the State of Delaware in August 1987.

Forward-Looking Statements

This press release contains forward-looking statements regarding future events and the future performance of Solitron Devices, Inc. that involve risks and uncertainties that could materially affect actual results, including statements regarding the Company's unaudited fiscal 2020 fourth quarter and fiscal year results and the Company's expectations regarding bookings, revenue, and net income in fiscal 2021. Factors that could cause actual results to vary from current expectations and forward-looking statements contained in this press release include, but are not limited to: (1) actual bookings, revenue and net income for fiscal year 2021; (2) the global impact of the pandemic outbreak of coronavirus (COVID-19) and its impact on our operations and the operations of our suppliers and clients, staffing levels and labor costs, the timing and size of orders from our clients, our delivery schedules and our liquidity and cash position (3) our ability to properly account for inventory in the future; (4) the successful resolution of the supplier issues and internal production challenges we experienced during the fiscal 2020 fourth quarter; (5) the timely and successful completion of our wafer fab improvement plan; (6) our ability to protect the Company's net operating losses and tax benefits; (7) volatility and changes in our stock price, corporate or other market conditions; (8) the loss of, or reduction of business from, substantial clients; (9) our dependence on government contracts, which are subject to termination, price renegotiations and regulatory compliance; (10) changes in government policy or economic conditions; (11) increased competition; (12) the uncertainty of current economic conditions, domestically and globally; and (13) other factors contained in the Company's Securities and Exchange Commission filings, including its most recent Form 10-K, 10-Q and 8-K reports.

Tim Eriksen
Chief Executive Officer
(561) 848-4311
Corporate@solitrondevices.com

SOURCE: Solitron Devices, Inc.

ReleaseID: 582736

NEW YORK, NY / ACCESSWIRE / March 26, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Tupperware Brands Corporation (NYSE:TUP)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/tupperware-brands-corporation-loss-submission-form?prid=5822&wire=1
Lead Plaintiff Deadline: April 27, 2020
Class Period: January 30, 2019 to February 24, 2020

Allegations against TUP include that: (1) Tupperware lacked effective internal controls; (2) as a result, Tupperware would need to investigate the accounting and liabilities of one of its brands, Fuller Mexico; (3) consequently, Tupperware would be unable to timely file its annual report on Form 10-K for its fiscal year 2019; (4) Tupperware did not properly account for its accounts payable and accrued liabilities at Fuller Mexico; (5) Tupperware provided overvalued earnings per share guidance; (6) Tupperware would need relief from its $650 million Credit Agreement; and (7) as a result, defendants' public statements were materially false and/or misleading at all relevant times.

Tivity Health, Inc. (NASDAQ:TVTY)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/tivity-health-inc-loss-submission-form?prid=5822&wire=1
Lead Plaintiff Deadline: April 27, 2020
Class Period: March 8, 2019 to February 19, 2020

Allegations against TVTY include that: (i) following the Nutrisystem Acquisition, Tivity's Nutrition segment faced significant operational challenges; (ii) the foregoing would foreseeably have a significant impact on Tivity's revenues; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Becton Dickinson & Company (NYSE:BDX)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/becton-dickinson-company-loss-submission-form?prid=5822&wire=1
Lead Plaintiff Deadline: April 27, 2020
Class Period: November 5, 2019 to February 5, 2020

Allegations against BDX include that: (1) certain of Becton's Alaris infusion pumps experienced software errors and alarm prioritization issues; (2) as a result, the Company was investing in remediation efforts to address these product issues, rather than a software upgrade to "make enhancements;" (3) the Company was reasonably likely to face regulatory delays in connection with the software remediation; (4) as a result of the foregoing, Becton was reasonably likely to recall certain of its Alaris infusion pumps; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong

ReleaseID: 582748

NAPLES, ITALY / ACCESSWIRE / March 26, 2020 / Aristide Tofani is a third generational neapolitan tailor and designer of Sartoria Tofani, a Neapolitan tailoring house founded in 1954.
During the last few years, Aristide shared his "artist lifestyle" on Instagram and grew an incredible number of followers. We had the pleasure to interview Aristide and ask him about the worldwide success of his family business and their wonderful bespoke suits.

Founded in 1954 and famous in the whole world, how did this incredible legacy start?
Sartoria Tofani was founded by my grandfather Aristide in 1954 in the heart of the historical center of Naples. My grandfather, first tailor of the family, thanks to his passion and devotion to this wonderful art was able to become a respected master tailor. When he was very young he studied with the best master tailors in Naples and during many years of apprenticeship he was able to turn his passion in his dream job.

An art passed down through generations, what is the secret that let Sartoria Tofani reach 70 years of successful business?
There is no secret or magic pill, the thing that let our tailoring reach 70 years is the way we conduct our life. Since a young age, every family member that joined our sartoria was literally raised in the shop.
I still remember when I was just a kid and used to spend hours and hours in our ancient shop "playing" with needles, fabrics and scissors. The elegance, the love for bespoke garments is something that we had since we were just childrens. Passion apart, I think that being extremely professional and respecting every client let us keep the same clients for generations.

What makes a Tofani suit so special?
Our suits follow the rules of the real handmade neapolitan suits. For example, our typical jacket is very soft and light, it doesn't have excessive padding. This light structure allows the jacket to follow the client's body structure and make his silhouette look better. Very often people may think that a light jacket is supposed to make much wrinkles, but our jackets, even if very light, keep that clean and elegant shape without excessive wrinkling.

What do you like most about being a Tailor?
The thing I like the most about being a tailor is that I had the honor to learn one of the most ancient and worldwide respected arts. Thanks to my family art I'm able to create excellence, to make luxury suits completely shaped to our customers desires. Being able to satisfy the desires of the refined men, showing with our garments personality, reliability, passion and competence.

How did you become the manager of your family business at such a young age, do you think you have a special entrepreneurial spirit?
I think no one is born with an entrepreneurial spirit, but most of the times entrepreneurs develop it growing up, in my opinion since a young age the mix of experiences we go through and the environment we grow into do a lot to develop an entrepreneurial spirit but this is just 30% of the work. Developing an entrepreneurial spirit requires hard work every day. You have to do little things that "hurt" every day, it might be writing extra emails, it might be staying late at work, whatever it is. It's all about challenging yourself and pushing yourself. How you do anything is how you do everything, I challenge myself to be a person who does, instead of a person who talks about doing. Make a resolution every day of your life, and take action.

Sixteen fashion shows a year in New York, Hong Kong, Paris and Zurich, how did you grow your client base so much in such a short time?
Traveling the world has always been one of my dreams, and when this dream matched with the needing and the requests of our clients worldwide I just took action. Many famous and busy entrepreneurs or amateurs desired our luxury bespoke services but they were too busy to reach us in Naples, so I just made it simple for them, this is my idea of a luxury service.

Do you plan to increase your reach?
Yes, we have many requests from the US and Asia, so I'm working to start hosting frequent shows in the west coast (San Francisco, Los Angeles etc.) and in the main cities of Asia (Tokyo, Seoul, Beijing).

Contact Info
Company: Sartoria Tofani
Email: sartoriatofani@gmail.com
Website: http://sartoriatofani.com/

SOURCE: Sartoria Tofani

ReleaseID: 582745

NEW YORK, NY / ACCESSWIRE / March 26, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

TLRY Shareholders Click Here: https://www.zlk.com/pslra-1/tilray-inc-loss-form?prid=5821&wire=1
CRON Shareholders Click Here: https://www.zlk.com/pslra-1/cronos-group-inc-loss-form-2?prid=5821&wire=1
XP Shareholders Click Here: https://www.zlk.com/pslra-1/xp-inc-loss-form?prid=5821&wire=1

* ADDITIONAL INFORMATION BELOW *

Tilray, Inc. (NASDAQ:TLRY)

TLRY Lawsuit on behalf of: investors who purchased January 15, 2019 – March 2, 2020
Lead Plaintiff Deadline : May 5, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/tilray-inc-loss-form?prid=5821&wire=1

According to the filed complaint, during the class period, Tilray, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the purported advantages of the marketing and revenue sharing agreement with Authentic Brands Group (the "ABG Agreement")were significantly overstated; (ii) the under performance of the ABG Agreement would foreseeably have a significant impact on the Company's financial results; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Cronos Group Inc. (NASDAQ:CRON)

CRON Lawsuit on behalf of: investors who purchased May 9, 2019 – March 2, 2020
Lead Plaintiff Deadline : May 11, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/cronos-group-inc-loss-form-2?prid=5821&wire=1

According to the filed complaint, during the class period, Cronos Group Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Cronos had engaged in significant transactions for which its revenue recognition was inappropriate; (ii) the foregoing would foreseeably necessitate reviews that would delay the Company's ability to timely file its periodic reports; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

XP Inc. (NASDAQ:XP)

XP Lawsuit on behalf of: investors who purchased or otherwise acquired XP's securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with XP's December 2019 initial public offering.
Lead Plaintiff Deadline : May 20, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/xp-inc-loss-form?prid=5821&wire=1

According to the filed complaint, (1) XP engaged in undisclosed related party transactions; (2) XP failed to disclose its common and large system failures and connected losses; (3) XP's aggressive IFA strategy was and is tenuous; (4) XP had material weaknesses; (5) XP fired its previous accounting firm due to that firm finding and disclosing material weaknesses; and (6) as a result, Defendants' public statements were materially false and misleading at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 582747

LOS ANGELES, CA / ACCESSWIRE / March 26, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against Tupperware Brands Corporation ("Tupperware" or "the Company") (NYSE:TUP) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between January 30, 2019 and February 24, 2020, inclusive (the ''Class Period''), are encouraged to contact the firm before April 27, 2020.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Tupperware failed to maintain appropriate internal controls. Based on this failure, the Company was forced to investigate the accounting and liabilities of its Fuller Mexico division. Due to this investigation, the Company delayed the filing of its annual report on Form 10-K for fiscal year 2019. The Company did not properly account for Fuller Mexico's accounts payable and accrued liabilities, resulting in it overvaluing its earnings per share guidance. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Tupperware, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 582743

LOS ANGELES, CA / ACCESSWIRE / March 26, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AnaptysBio, Inc. ("AnaptysBio" or "the Company") (NASDAQ:ANAB) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between October 10, 2017 and November 7, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before May 26, 2020.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. AnaptysBio failed to include crucial information in its Phase 2a trial for atopic dermatitis, such as the timing and extent of patients' use of topical corticosteroids as a rescue therapy. The Company also failed to include important information in its Phase 2a trial for peanut allergies, such as the cumulative peanut dose tolerated at day 14 after the administration of etokimab or placebo. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about AnaptysBio, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 582742

LOS ANGELES, CA / ACCESSWIRE / March 26, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against Becton, Dickinson and Company ("Becton Dickinson" or "the Company") (NYSE:BDX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between November 5, 2019 and February 5, 2020, inclusive (the ''Class Period''), are encouraged to contact the firm before April 27, 2020.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Becton Dickinson's Alaris infusion pumps suffered from software errors and alarm issues. The Company invested its resources in remediation efforts instead of software upgrades to "make enhancements." These software errors were likely to cause regulatory delays for the Company, and it would be forced to recall Alaris pumps from some customers. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Becton Dickinson, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.
310-301-3335
info@schallfirm.com
www.schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 582741

LOS ANGELES, CA / ACCESSWIRE / March 26, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Expedia Group, Inc. ("Expedia" or "the Company") (NASDAQ:EXPE) for violations of securities laws.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 582737